Skip to main navigation Skip to search Skip to main content

Botulinum toxin for symptomatic therapy in multiple sclerosis

  • Michelle H. Cameron
  • , Francois Bethoux
  • , Nina Davis
  • , Meredith Frederick

Research output: Contribution to journal › Article › peer-review

Abstract

Botulinum toxin (BT) is a neurotoxin that paralyzes muscles by inhibiting release of acetylcholine from presynaptic vesicles at the neuromuscular junction. In people with multiple sclerosis (MS), clinical experience and research studies show that local injection of minute quantities of BT can temporarily control skeletal muscle spasticity, bladder detrusor hyperreflexia, and tremor. Specifically, BT injections have been shown to reduce muscle tone and improve passive function, and possibly improve active function, in patients with spasticity. Injection of BT into the bladder wall is a uniquely effective, safe, and durable treatment in patients with neurogenic detrusor hyperreflexia due to MS who have insufficient response or who do not tolerate oral antimuscarinic medications. This procedure has markedly reduced the need for indwelling catheters and bladder surgery. In addition, a recent study suggests BT may be effective for select patients with MS-associated upper extremity tremor. Appropriate use of BT can improve quality of life for many patients with MS.

Original languageEnglish (US)
Article number463
JournalCurrent neurology and neuroscience reports
Volume14
Issue number8
DOIs
StatePublished - Aug 2014

Funding

Francois Bethoux has received consultancy fees from Concert Pharmaceuticals, Merz Pharma, Medtronic, and GW Pharma, along with grants from Merz Pharma and Medtronic. He has also received payments from Allergan for development of educational presentations.

Funders
Medtronic
Merz Pharmaceuticals

    Keywords

    • Botulinum toxin
    • Incontinence
    • Multiple sclerosis
    • Spasticity
    • Tremor

    ASJC Scopus subject areas

    • General Neuroscience
    • Clinical Neurology

    Fingerprint

    Dive into the research topics of 'Botulinum toxin for symptomatic therapy in multiple sclerosis'. Together they form a unique fingerprint.

    Cite this